UPDATE – August 3, 2024: Teva Canada Ltd. is expanding its recall to all lots of ratio-ECTOSONE (TEVA-ECTOSONE) 0.1% regular lotion and ratio-ECTOSONE (TEVA-ECTOSONE) 0.05% mild lotion after testing detected the same impurity, betamethasone enol aldehyde, above the accepted limit in some additional lots. In addition, the products are being recalled because of labelling errors, including dosing instructions. The labels state "once or twice daily" when they should say "two to three times daily." Following the incorrect dosing instructions on the label may decrease the product's overall effectiveness in relieving skin conditions. Original Advisory – June 28, 2024: One lot of ratio-ECTOSONE (TEVA-ECTOSONE) 0.05% mild lotion recalled due to an impurity that may pose health risks Teva Canada Ltd. is recalling one lot of ratio-ECTOSONE (TEVA-ECTOSONE) 0.05% mild lotion in 60 mL bottles. This action follows testing that detected an impurity—betamethasone enol aldehyde—above the accepted limit in the affected lot. This impurity can form due to a chemical change in the drug during storage and may pose health risks, including the possibility of adverse reactions on the skin or elsewhere in the body from being absorbed into the bloodstream. The risk may be greater in children who may absorb proportionally larger amounts of the impurity and be more susceptible to adverse reactions. The product is a prescription corticosteroid lotion used to relieve skin inflammation and itch caused by skin conditions such as eczema, psoriasis and dermatitis. The affected lot was distributed to pharmacies in Canada between November 24, 2022 and March 22, 2023. Health Canada is monitoring the company's recall, and its implementation of any necessary corrective and preventative actions to prevent this issue from reoccurring.